Pathogenic involvement of neuropeptides in anxiety and depression

Neuropeptides

Volumn 44, Issue 3, 2010, Pages 215-224

  Alldredge, B ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; ARGININE VASOPRESSIN ANTAGONIST; ARGIPRESSIN; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; G PROTEIN COUPLED RECEPTOR; GALANIN; GALANIN RECEPTOR 3; MELANIN CONCENTRATING HORMONE; MELANIN CONCENTRATING HORMONE RECEPTOR 1 ANTAGONIST; NEUROPEPTIDE; NEUROPEPTIDE S; NEUROPEPTIDE Y; OXYTOCIN; PROTEIN INHIBITOR; SUBSTANCE P; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; VAPTAN DERIVATIVE;

ANXIETY; ANXIETY DISORDER; DEPRESSION; DYSMENORRHEA; ENZYME ACTIVITY; ENZYME MECHANISM; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; HUMAN; HYPONATREMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INAPPROPRIATE VASOPRESSIN SECRETION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RAYNAUD PHENOMENON; REVIEW; SEXUAL DYSFUNCTION; STRESS; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT;

ADAPTATION, PSYCHOLOGICAL; ANIMALS; ANXIETY DISORDERS; DEPRESSIVE DISORDER; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MICE; NEUROPEPTIDES; RATS; STRESS DISORDERS, POST-TRAUMATIC; STRESS, PSYCHOLOGICAL;

EID: 77951204769     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2009.12.014     Document Type: Review

References (150)

1. Aguilera G., Subburaju S., Young S., Chen J. The parvocellular vasopressinergic system and responsiveness of the hypothalamic pituitary adrenal axis during chronic stress. Prog. Brain Res. 2008, 170:29-39.
2. Albert P.R., Lemonde S. 5-HT1A receptors, gene repression, and depression: guilt by association. Neuroscientist 2004, 10:575-593.
3. Amico J.A., Mantella R.C., Vollmer R.R., Li X. Anxietyand stress responses in femaleoxytocindeficient mice. J. Neuroendocrinol. 2004, 16:319-324.
4. Amico J.A., Cai H.M., Vollmer R.R. Corticosterone release inoxytocingene deletion mice following exposure to psychogenic versus non-psychogenicstress. Neurosci. Lett. 2008, 442:262-266.
5. Antoni F.A. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol. 1993, 14:76-122.
6. Bacchi F., Mathé A.A., Jiménez P., Stasi L., Arban R., Gerrard P., Caberlotto L. Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze. Peptides 2006, 27:3202-3207.
7. Bailey K.R., Pavlova M.N., Rohde A.D., Hohmann J.G., Crawley J.H. Galanin receptor subtype 2 (GalR2) null mutant mice display an anxiogenic-like phenotype specific to the elevated plus-maze. Pharmacol. Biochem. Behav. 2007, 86:8-20.
8. Barr A.M., Kinney J.W., Hill M.N., Lu X., Biros S., Rebek J., Bartfai T. A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests. Neurosci. Lett. 2006, 405:111-115.
9. Binneman B., Feltner D., Kolluri S., Shi Y., Qiu R., Stiger T. A 6-week randomized, placebo-controlled trial of CP-316, 311 (a selective CRH1 antagonist) in the treatment of major depression. Am. J. Psychiatry 2008, 165:617-620.
10. Bissette G., Klimek V., Pan J., Stockmeier C., Ordway G. Elevated concentrations of CRF in the locus coeruleus of depressed subjects. Neuropsychopharmacology 2003, 28:1328-1335.
11. Bleickardt C.J., Mullins D.E., Macsweeney C.P., Werner B.J., Pond A.J., Guzzi M.F., Martin F.D., Varty G.B., Hodgson R.A. Characterization of the V1a antagonist, JNJ-17308616, in rodent models ofanxiety-like behavior. Psychopharmacology 2009, 202:711-718.
12. Blier P., Gobbi G., Haddjeri N., Santarelli L., Mathew G., Hen R. Impact of substance P receptorantagonismon the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response. J. Psychiatry Neurosci. 2004, 29:201-208.
13. Bradley R.G., Binder E.B., Epstein M.P., Tang Y., Nair H.P., Liu W., Gillespie C.F., Berg T., Evces M., Newport D.J., Stowe Z.N., Heim C.M., Nemeroff C.B., Schwartz A., Cubells J.F., Ressler K.J. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch. Gen. Psychiatry 2008, 65:190-200.
14. Britton K.T., Akwa Y., Spina M.G., Koob G.F. Neuropeptide Y blocks anxiogenic-like behavioral action of corticotropin-releasing factor in an operant conflict test and elevated plus maze. Peptides 2000, 21:37-44.
15. Caldwell H.K., Lee H.J., Macbeth A.H., Young W.S. Vasopressin: behavioral roles of an " original" neuropeptide. Prog. Neurobiol. 2008, 84:1-24.
16. Campbell A. Attachment, aggression and affiliation: the role ofoxytocinin female social behavior. Biol. Psychol. 2008, 77:1-10.
17. Chaki S., Yamaguchi J., Yamada H., Thomsen W., Tran T.A., Semple G., Sekiguchi Y. ATC0175: an orally active melanin-concentrating hormone receptor 1 antagonist for the potential treatment of depression and anxiety. CNS Drug Rev. 2005, 11:341-352.
18. Chen J., Young S., Subburaju S., Sheppard J., Kiss A., Atkinson H., Wood S., Lightman S., Serradeil-Le Gal C., Aguilera G. Vasopressin does not mediate hypersensitivity of the hypothalamic pituitary adrenal axis during chronic stress. Ann. NY Acad. Sci. 2008, 1148:349-359.
19. Chenu F., Guiard B.P., Bourin M., Gardier A.M. Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test. Behav. Brain Res. 2006, 172:256-263.
20. Cyranowski J.M., Hofkens T.L., Frank E., Seltman H., Cai H.M., Amico J.A. Evidence of dysregulated peripheraloxytocinrelease among depressed women. Psychosom. Med. 2008, 70:967-975.
21. de Kloet E.R., Joëls M., Holsboer F. Stressand the brain: from adaptation to disease. Nat. Rev. Neurosci. 2005, 6:463-475.
22. Decaux G., Soupart A., Vasart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 2008, 371:1624-1632.
23. Dempster E.L., Burcescu I., Wigg K., Kiss E., Baji I., Gadoros J., Tamás Z., Kennedy J.L., Vetró A., Kovacs M., Barr C.L. Evidenceof anassociationbetween thevasopressin V1b receptorgene(AVPR1B) andchildhood-onsetmood disorders. Arch. Gen. Psychiatry 2007, 64:1189-1195.
24. Dinan T.G., Scott L.V. Anatomyofmelancholia:focusonhypothalamic-pituitary-adrenalaxisoveractivityand theroleofvasopressin. J. Anat. 2005, 207:259-264.
25. Duric V., McCarson K.E. Hippocampal neurokinin-1 receptor and brain-derived neurotrophic factor gene expression is decreased in rat models of pain and stress. Neuroscience 2005, 133:999-1006.
26. Eaton K., Sallee F.R., Sah R. Relevance of neuropeptide Y (NPY) in psychiatry. Curr. Top. Med. Chem. 2007, 7:1645-1659.
27. Ebner K., Singewald N. The role of substance P in stress and anxiety responses. Amino Acids 2006, 31:251-272.
28. Ebner K., Singewald N. Stress-induced release ofsubstance Pin the locus coeruleus modulates cortical noradrenaline release. Naunyn Schmiedebergs Arch. Pharmacol. 2007, 376:73-78.
29. Ebner K., Rupniak N.M., Saria A., Singewald N. Substance Pin the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc. Natl. Acad. Sci. USA 2004, 101:4280-4285.
30. Ebner K., Muigg P., Singewald G., Singewald N. Substance Pin stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry. Ann. NY Acad. Sci. 2008, 1144:61-73.
31. Ebner K., Sartori S.B., Singewald N. Tachykinin receptors as therapeutic targets in stress-related disorders. Curr. Pharm. Des. 2009, 15:1647-1674.
32. Egashira N., Tanoue A., Matsuda T., Koushi E., Harada S., Takano Y., Tsujimoto G., Mishima K., Iwasaki K., Fujiwara M. Impaired social interaction and reducedanxiety-related behavior invasopressinV1a receptorknockoutmice. Behav. Brain Res. 2007, 178:123-127.
33. Elliott-Hunt C.R., Pope R.J., Vanderplank P., Wynick D. Activation of the galanin receptor 2 (GalR2) protects the hippocampus from neuronal damage. J. Neurochem. 2007, 100:780-789.
34. Figueira M.L., Ouakinin S. From psychosomatic to psychological medicine: what's the future?. Curr. Opin. Psychiatry 2008, 21:412-416.
35. Forster G.L., Pringle R.B., Mouw N.J., Vuong S.M., Watt M.J., Burke A.R., Lowry C.A., Summers C.H., Renner K.J. Corticotropin-releasing factor in the dorsal raphe nucleus increases medial prefrontal cortical serotonin via type 2 receptors and median raphe nucleus activity. Eur. J. Neurosci. 2008, 28:299-310.
36. Furmark T., Appel L., Michelgård A., Wahlstedt K., Ahs F., Zancan S., Jacobsson E., Flyckt K., Grohp M., Bergström M., Pich E.M., Nilsson L.G., Bani M., Långström B., Fredrikson M. Cerebral blood flow changes aftertreatmentofsocialphobiawith theneurokinin-1antagonist GR205171, citalopram, or placebo. Biol. Psychiatry 2005, 58:132-142.
37. Georgescu D., Sears R.M., Hommel J.D., Barrot M., Bolaños C.A., Marsh D.J., Bednarek M.A., Bibb J.A., Maratos-Flier E., Nestler E.J., DiLeone R.J. The hypothalamic neuropeptide melanin-concentrating hormone acts in the nucleus accumbens to modulate feeding behavior and forced-swim performance. J. Neurosci. 2005, 25:2933-2940.
38. Gimpl G., Fahrenholz F. Theoxytocinreceptor system: structure, function, and regulation. Physiol. Rev. 2001, 81:629-683.
39. Gorman J.M. Comorbiddepression and anxietyspectrumdisorders. Depress. Anxiety 1996, 4:160-168.
40. Greibel G., Stemmelin J., Serradeil-Le Gal C., Soubrie P. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. Curr. Pharm. Des. 2005, 11:1549-15559.
41. Guastella A.J., Howard A.L., Dadds M.R., Mitchell P., Carson D.S. A randomized controlled trial of intranasaloxytocinas an adjunct to exposure therapy forsocial anxiety disorder. Psychoneuroendocrinology 2009, 34:917-923.
42. Guiard B.P., Przybylski C., Guilloux J.P., Seif I., Froger N., De Felipe C., Hunt S.P., Lanfumey L., Gardier A.M. Blockade of substance P (neurokinin1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. J. Neurochem. 2004, 89:54-63.
43. Gutman A.R., Yang Y., Ressler K.J., Davis M. TheroleofneuropeptideYin theexpressionandextinctionoffear-potentiatedstartle. J. Neurosci. 2008, 28:12682-12690.
44. Habib K.E., Weld K.P., Rice K.C., Pushkas J., Champoux M., Listwak S., Webster E.L., Atkinson A.J., Schulkin J., Contoreggi C., Chrousos G.P., McCann S.M., Suomi S.J., Higley J.D., Gold P.W. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc. Natl. Acad. Sci. USA 2000, 97:6079-6084.
45. Hamke M., Herpfer I., Lieb K., Wandelt C., Fiebich B.L. Substance Pinduces expression of the corticotropin-releasing factor receptor 1 by activation of the neurokinin-1 receptor. Brain Res. 2006, 1102:135-144.
46. Hammen C. Stressand depression. Annu. Rev. Clin. Psychol. 2005, 1:293-319.
47. Heilig M. TheNPYsystem in stress, anxiety and depression. Neuropeptides 2004, 38:213-224.
48. Heilig M., Söderpalm B., Engel J.A., Widerlöv E. Centrally administeredneuropeptide Y(NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology (Berl) 1989, 98:524-529.
49. Heim C., Plotsky P.M., Nemeroff C.B. Importanceof studying the contributions of early adverse experience to neurobiological findings in depression. Neuropsychopharmacology 2004, 29:641-648.
50. Heinrichs S.C., Koob G.F. Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulation. J. Pharmacol. Exp. Ther. 2004, 311:427-440.
51. Hervieu G.J., Cluderay J.E., Harrison D., Meakin J., Maycox P., Nasir S., Leslie R.A. The distribution of the mRNA and protein products of the melanin-concentrating hormone (MCH) receptor gene, slc-1, in the central nervous system of the rat. Eur. J. Neurosci. 2000, 12:1194-1216.
52. Hindmarch I. Beyondthemonoaminehypothesis: mechanisms, molecules and methods. Eur. Psychiatry 2002, 17(Suppl. 3):294-299.
53. Hobson S.A., Bacon A., Elliot-Hunt C.R., Holmes F.E., Kerr N.C., Pope R., Vanderplank P., Wynick D. Galanin acts as a trophic factor to the central and peripheral nervous systems. Cell Mol. Life Sci. 2008, 65:1806-1812.
54. Hodgson R.A., Higgins G.A., Guthrie D.H., Lu S.X., Pond A.J., Mullins D.E., Guzzi M.F., Parker E.M., Varty G.B. Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154, 526, in rodent models of anxiety and depression. Pharmacol. Biochem. Behav. 2007, 86:431-440.
55. Hoge E.A., Pollack M.H., Kaufman R.E., Zak P.J., Simon N.M. Oxytocinlevels in social anxiety disorder. CNS Neurosci. Ther. 2008, 14:165-170.
56. Hökfelt T., Broberger C., Xu Z.Q., Sergeyev V., Ubink R., Diez M. Neuropeptides - an overview. Neuropharmacology 2000, 39:1337-1356.
57. Holsboer F. Thecorticosteroid receptorhypothesis ofdepression. Neuropsychopharmacology 2000, 23:477-501.
58. Huber D., Veinante P., Stoop R. Vasopressin andoxytocinexcite distinct neuronal populations in the central amygdala. Science 2005, 308:245-248.
59. Jüngling K., Seidenbecher T., Sosulina L., Lesting J., Sangha S., Clark S.D., Okamura N., Duangdao D.M., Xu Y.L., Reinscheid R.K., Pape H.C. NeuropeptideS-mediated control of fear expression and extinction: role of intercalated GABAergic neurons in theamygdala. Neuron 2008, 59:298-310.
60. Karlsson R.M., Holmes A. Galanin as a modulator of anxiety and depression and a therapeutic target for affective disease. Amino acids 2006, 31:231-239.
61. Kask A., Harro J., von Hörsten S., Redrobe J.P., Dumont Y., Quirion R. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects ofneuropeptide Y. Neurosci. Biobehav. Rev. 2002, 26:258-259.
62. Keck M.E., Welt T., Müller M.B., Landgraf R., Holsboer F. The high-affinity non-peptide CRH1 receptorantagonistR121919 attenuates stress-induced alterations in plasma oxytocin, prolactin, and testosterone secretion in rats. Pharmacopsychiatry 2003, 36:27-31.
63. Keck M.E., Kern N., Erhardt A., Unschuld P.G., Ising M., Salyakina D., Müller M.B., Knorr C.C., Lieb R., Hohoff C., Krakowitzky P., Maier W., Bandelow B., Fritze J., Deckert J., Holsboer F., Müller-Myhsok B., Binder E.B. Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study forpanicdisorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147B:1196-1204.
64. Keen-Rhinehart E., Michopoulos V., Toufexis D.J., Martin E.I., Nair H., Ressler K.J., Davis M., Owens M.J., Nemeroff C.B., Wilson M.E. Continuous expression of corticotropin-releasing factor in the central nucleus of the amygdala emulates the dysregulation of the stress and reproductive axes. Mol. Psychiatry 2009, 14:37-50.
65. Kehne J.H. The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders. CNS Neurol. Disord. Drug Targets 2007, 6:163-168.
66. Keller M., Montgomery S., Ball W., Morrison M., Snavely D., Liu G., Hargreaves R., Hietala J., Lines C., Beebe K., Reines S. Lack of efficacy of the substance p (neurokinin1 receptor)antagonistaprepitant in the treatment of major depressive disorder. Biol. Psychiatry 2006, 59:216-223.
67. Kennedy A.R., Todd J.F., Dhillo W.S., Seal L.J., Ghatei M.A., O'Toole C.P., Jones M., Witty D., Winborne K., Riley G., Hervieu G., Wilson S., Bloom S.R. Effect of direct injection of melanin-concentrating hormone into the paraventricular nucleus: further evidence for a stimulatory role in the adrenal axis via SLC-1. J. Neuroendocrinol. 2003, 15:268-272.
68. Koob G.F. Corticotropin-releasing factor, norepinephrine, andstress. Biol. Psychiatry 1999, 46:1167-1180.
69. Kramer M.S., Winokur A., Kelsey J., Preskorn S.H., Rothschild A.J., Snavely D., Ghosh K., Ball W.A., Reines S.A., Munjack D., Apter J.T., Cunningham L., Kling M., Bari M., Getson A., Lee Y. Demonstration of the efficacy and safety of a novel substance P (NK1) receptorantagonistin major depression. Neuropsychopharmacology 2004, 29:385-392.
70. Kuteeva E., Hokefelt T., Wardi T., Ogren S.O. Galanin, galanin receptor subtypes and depression-like behavior. Cell Mol. Life Sci. 2008, 65:1854-1863.
71. Lage R., Diéguez C., López M. Caffeine treatment regulatesneuropeptideSsystem expression in the rat brain. Neurosci. Lett. 2006, 410:47-51.
72. Lage R., González C.R., Diéguez C., López M. Nicotine treatment regulatesneuropeptideSsystem expression in the rat brain. Neurotoxicology 2007, 28:1129-1135.
73. Leonard S.K., Dwyer J.M., Rizzo Sukoff S J, Platt B., Logue S.F., Neal S.J., Malberg J.E., Beyer C.E., Schechter L.E., Rosenzweig-Lipson S., Ring R.H. Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders. Psychopharmacology (Berl) 2008, 197:601-611.
74. Licinio J., O'Kirwan F., Irizarry K., Merriman B., Thakur S., Jepson R., Lake S., Tantisira K.G., Weiss S.T., Wong M.L. Association of a corticotropin-releasing hormone receptor 1haplotypeand antidepressant treatment response in Mexican-Americans. Mol. Psychiatry 2004, 9:1075-1082.
75. Liu Z., Zhu F., Wang G., Xiao Z., Wang H., Tang J., Wang X., Qiu D., Liu W., Cao Z., Li W. Association of corticotropin-releasing hormone receptor1 geneSNPand haplotype with major depression. Neurosci. Lett. 2006, 404:358-362.
76. Liu Z., Zhu F., Wang G., Xiao Z., Tang J., Liu W., Wang H., Liu H., Wang X., Wu Y., Cao Z., Li W. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressantresponsein major depressive disorders. Neurosci. Lett. 2007, 414:155-158.
77. Louis C., Cohen C., Depoortère R., Griebel G. Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat. Neuropsychopharmacology 2006, 31:2180-2187.
78. Louis C., Stemmelin J., Boulay D., Bergis O., Cohen C., Griebel G. Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), anantagonistat theneurokinin-2 receptor in various rodent-models. Pharmacol. Biochem. Behav. 2008, 89:36-45.
79. Lu X., Barr A.M., Kinney J.W., Sanna P., Conti B., Behrens M.M., Bartfai T. A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus. Proc. Natl. Acad. Sci. USA 2005, 102:874-879.
80. Lu X., Ross B., Sanchez-Alavez M., Zorrilla E.P., Bartfai T. Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests. Neuropeptides 2008, 42:387-397.
81. Ma Q.P., Bleasdale C. Modulation of brain stem monoamines and gamma-aminobutyric acid by NK1 receptors in rats. Neuroreport 2002, 13:1809-1812.
82. Maggi C.A. The mammalian tachykininreceptors. Gen. Pharmacol. 1995, 26:911-944.
83. Makino S., Smith M.A., Gold P.W. Increased expression of corticotropin-releasing hormone and vasopressin messenger ribonucleic acid (mRNA) in the hypothalamic paraventricular nucleus during repeated stress: association with reduction in glucocorticoid receptor mRNA levels. Endocrinology 1995, 136:3299-3309.
84. Marsteller D.A., Gerald C.P., Kong R., Cajina M., Craig D.A., Swanson C.J. The MCH1 receptor antagonist SNAP 94847 induces sensitivity to dopamine D2/D3 receptor agonists in rats and mice. Eur. J. Pharmacol. 2009, 602:66-72.
85. Mechenthaler I. Galanin and the neuroendocrine axes. Cell Mol. Life Sci. 2008, 65:1826-1835.
86. Merali Z., Du L., Hrdina P., Palkovits M., Faludi G., Poulter M.O., Anisman H. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J. Neurosci. 2004, 24:1478-1485.
87. Micale V., Tamburella A., Leggio G.M., Mazzola C., Li Volsi V., Drago F. Behavioral effects of saredutant, a tachykinin NK2 receptorantagonist, in experimental models of mood disorders under basal and stress-related conditions. Pharmacol. Biochem. Behav. 2008, 90:463-469.
88. Millan M.J., Gobert A., Panayi F., Rivet J.M., Dekeyne A., Brocco M., Ortuno J.C., Di Cara B. The melanin-concentrating hormone1 receptor antagonists, SNAP-7941 and GW3430, enhance social recognition and dialysate levels of acetylcholine in the frontal cortex of rats. Int. J. Neuropsychopharmacol. 2008, 11:1105-1122.
89. Mistsukawa K., Lu X., et al. Galanin, galanin receptors and drug targets. Cell Mol. Life Sci. 2008, 65:1796-1805.
90. Morgan C.A., Wang S., Southwick S.M., Rasmusson A., Hazlett G., Hauger R.L., Charney D. Plasma neuropeptide-Y concentrations in humans exposed to military survival training. Biol. Psychiatry 2000, 47:902-909.
91. Müller M.B., Zimmermann S., Sillaber I., Hagemeyer T.P., Deussing J.M., Timpl P., Kormann M.S., Droste S.K., Kühn R., Reul J.M., Holsboer F., Wurst W. Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat. Neurosci. 2003, 6:1100-1107.
92. Nakajima M., Inui A., Asakawa A., Momose K., Ueno N., Teranishi A., Baba S., Kasuga M. NeuropeptideY producesanxietyviaY2-type receptors. Peptides 1998, 19:359-363.
93. Nemeroff C.B., Vale W.W. The neurobiology of depression:inroadsto treatment and new drug discovery. Clin. Psychiatry 2005, 66(Suppl. 7):5-13.
94. Nemeroff C.B., Widerlöv E., Bissette G., Walléus H., Karlsson I., Eklund K., Kilts C.D., Loosen P.T., Vale W. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984, 226:1342-1344.
95. Nemeroff C.B., Owens M.J., Bissette G., Andorn A.C., Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch. Gen. Psychiatry 1988, 45:577-579.
96. Nemeroff C.B., Bissette G., Akil H., Fink M. Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin. Br. J. Psychiatry 1991, 158:59-63.
97. Nikisch G., Agren H., Eap C.B., Czernik A., Baumann P., Mathé A.A. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int. J. Neuropsychopharmacol. 2005, 8:403-410.
98. Nomura M., Saito J., Ueta Y., Muglia L.J., Pfaff D.W., Ogawa S. Enhanced up-regulation of corticotropin-releasing hormone gene expression in response to restraint stress in the hypothalamic paraventricular nucleus ofoxytocingene-deficient male mice. J. Neuroendocrinol. 2003, 15:1054-1061.
99. Ogren S.O., Kuteeva E., Hökfelt T., Kehr J. Galaninreceptor antagonists: a potential novel pharmacological treatment for mood disorders. CNS Drugs 2006, 20:633-635.
100. Ogren S.O., Razani H., Elvander-Tottie E., Kehr J. The neuropeptidegalaninas an in vivo modulator of brain 5-HT1A receptors: possible relevance for affective disorders. Physiol. Behav. 2007, 92:172-179.
101. Okamura N., Hashimoto K., Iyo M., Shimizu E., Dempfle A., Friedel S., Reinscheid R.K. Gender-specific association of a functional coding polymorphism in theNeuropeptideSreceptor gene with panic disorder but not with schizophrenia or attention-deficit/hyperactivity disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1444-1448.
102. Pañeda C., Huitron-Resendiz S., Frago L.M., Chowen J.A., Picetti R., de Lecea L., Roberts A.J. NeuropeptideSreinstatescocaine-seeking behavior and increases locomotor activity through corticotropin-releasing factor receptor 1 in mice. J. Neurosci. 2009, 29:4155-4161.
103. Phelps E.A., LeDoux J.E. Contributionsof theamygdalato emotion processing: from animal models to human behavior. Neuron 2005, 48:175-187.
104. Plotsky P.M., Thrivikraman K.V., Nemeroff C.B., Caldji C., Sharma S., Meaney M.J. Long-termconsequences of neonatal rearing on central corticotropin-releasing factor systems in adult male rat offspring. Neuropsychopharmacology 2005, 30:2192-2204.
105. Purba J., Hoogendijk W., Hoffman M., Swaab D. Increased numbers of vasopressin- and oxytocin-containing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch. Gen. Psychiatry 1996, 53:137-143.
106. Rainnie D.G., Bergeron R., Sajdyk T.J., Patil M., Gehlert D.R., Shekhar A. Corticotrophin releasing factor-induced synaptic plasticity in theamygdalatranslates stress into emotional disorders. J. Neurosci. 2004, 24:3471-3479.
107. Raiteri L., Luccini E., Romei C., Salvadori S., Calò G. NeuropeptideSselectively inhibits the release of 5-HT and noradrenaline from mouse frontal cortex nerve endings. Br. J. Pharmacol. 2009, 157:474-481.
108. Redrobe J.P., Dumont Y., Fournier A., Baker G.B., Quirion R. Role ofserotonin(5-HT) in the antidepressant-like properties ofneuropeptide Y(NPY) in the mouse forced swim test. Peptides 2005, 26:1394-1400.
109. Reinscheid R.K., Xu Y.L., Okamura N., Zeng J., Chung S., Pai R., Wang Z., Civelli O. Pharmacological characterization of human and murine neuropeptide s receptor variants. J. Pharmacol. Exp. Ther. 2005, 315:1338-1345.
110. Renoldi G., Invernizzi R.W. Blockade of tachykinin NK1 receptors attenuates stress-induced rise of extracellular noradrenaline and dopamine in the rat and gerbil medial prefrontal cortex. J. Neurosci. Res. 2006, 84:961-968.
111. Reul J.M., Holsboer F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr. Opin. Pharmacol. 2002, 2:23-33.
112. Ribeiro S.J., Teixeira R.M., Calixto J.B., De Lima T.C. Tachykinin NK(3)receptor involvement in anxiety. Neuropeptides 1999, 33:181-188.
113. Ring R.H., Malberg J.E., Potestio L., Ping J., Boikess S., Luo B., Schechter L.E., Rizzo S., Rahman Z., Rosenzweig-Lipson S. Anxiolytic-like activity of oxytocin in male mice. behavioral and autonomic evidence, therapeutic implications. Psychopharmacology (Berl) 2006, 185:218-225.
114. Ring, R.H., Schechter, L.E., Leonard, S.K., Dwyer, J.M., Platt, B.J., Graf, R., Grauer, S., Pulicicchio, C., Resnick, L., Rahman, Z., Sukoff Rizzo, S.J., Luo, B., Beyer, C.E., Logue, S.F., Marquis, K.L., Hughes, Z.A., Rosenzweig-Lipson, S., 2009. Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology (Epub ahead of print).
115. Rizzi A., Vergura R., Marzola G., Ruzza C., Guerrini R., Salvadori S., Regoli D., Calo G. NeuropeptideSis a stimulatory anxiolytic agent: a behavioural study in mice. Br. J. Pharmacol. 2008, 154:471-479.
116. Rosenkranz M.A. Substance Pat the nexus of mind and body in chronic inflammation and affective disorders. Psychol. Bull. 2007, 133:1007-1037.
117. Roy M., David N.K., Danao J.V., Baribault H., Tian H., Giorgetti M. Genetic inactivation of melanin-concentrating hormone receptor subtype 1 (MCHR1) in mice exerts anxiolytic-like behavioral effects. Neuropsychopharmacology 2006, 31:112-120.
118. Sajdyk T.J., Fitz S.D., Shekhar A. The role of neuropeptide Y in the amygdala on corticotropin-releasing factor receptor-mediated behavioral stress responses in the rat. Stress 2006, 9:21-28.
119. Sajdyk T.J., Johnson P.L., Leitermann R.J., Fitz S.D., Dietrich A., Morin M., Gehlert D.R., Urban J.H., Shekhar A. Neuropeptide Y in the amygdala induces long-term resilience to stress-induced reductions in social responses but not hypothalamic-adrenal-pituitary axis activity or hyperthermia. J. Neurosci. 2008, 28:893-903.
120. Santarelli L., Gobbi G., Debs P.C., Sibille E.T., Blier P., Hen R., Heath M.J. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc. Natl. Acad. Sci. USA 2001, 98:1912-1917.
121. Sartori S.B., Ebner K., Muigg P., Landgraf R., Singewald N. Differences in substance P neurotransmission between rats with high vs low trait anxiety/depression. J. Neurochem. 2005, 94:229.
122. Sawchenko P.E., Swanson L.W., Grzanna R., Howe P.R., Bloom S.R., Polak J.M. Colocalization ofneuropeptide Yimmunoreactivity in brainstem catecholaminergic neurons that project to the paraventricular nucleus of the hypothalamus. J. Comp. Neurol. 1985, 241:138-153.
123. Scantamburlo G., Hansenne M., Fuchs S., Pitchot W., Maréchal P., Pequeux C., Ansseau M., Legros J.J. Plasma oxytocin levels and anxiety in patients with major depression. Psychoneuroendocrinology 2007, 32:407-410.
124. Schmidt E.D., Bennekade R., Janszen A.W., Tilders F.J. Short stressor induced long-lasting increases of vasopressin stores in hypothalamic corticotropin-releasing hormone (CRH) neurons in adult rats. J Neuroendocrinol 1996, 8:703-712.
125. Serradeil-Le Gal C., Wagnon J., Tonnerre B., Roux R., Garcia G., Griebel G., Aulombard A. An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders. CNS Drug Rev. 2005, 11:53-68.
126. Shimazaki T., Yoshimizu T., Chaki S. Melanin-concentrating hormone MCH1 receptor antagonists: a potential new approach to the treatment of depression and anxiety disorders. CNS Drugs 2006, 20:801-811.
127. Simon N.G., Guillon C., Fabio K., Heindel N.D., Lu S.F., Miller M., Ferris C.F., Brownstein M.J., Garripa C., Koppel G.A. Vasopressin antagonists as anxiolytics and antidepressants: recent developments. Recent Pat. CNS Drug Discov. 2008, 3:77-93.
128. Smith P.W., Dawson L.A. Neurokinin 3 (NK3) receptor modulators for the treatment of psychiatric disorders. Recent Pat. CNS Drug Discov. 2008, 3:1-15.
129. Smith K.L., Patterson M., Dhillo W.S., Patel S.R., Semjonous N.M., Gardiner J.V., Ghatei M.A., Bloom S.R. NeuropeptideSstimulatesthehypothalamo-pituitary-adrenalaxisandinhibitsfood intake. Endocrinology 2006, 147:3510-3518.
130. Smith D.G., Hegde L.G., Wolinsky T.D., Miller S., Papp M., Ping X., Edwards T., Gerald C.P., Craig D.A. The effects of stressful stimuli and hypothalamic-pituitary-adrenal axis activation are reversed by the melanin-concentrating hormone 1 receptor antagonist SNAP 94847 in rodents. Behav. Brain Res. 2009, 197:284-291.
131. Sørensen G., Lindberg C., Wörtwein G., Bolwig T.G., Woldbye D.P. Differentialroles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation. J. Neurosci. Res. 2004, 77:723-729.
132. Steinberg R., Alonso R., Griebel G., Bert L., Jung M., Oury-Donat F., Poncelet M., Gueudet C., Desvignes C., Le Fur G., Soubrié P. Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J. Pharmacol. Exp. Ther. 2001, 299:449-458.
133. Stout S.C., Owens M.J., Nemeroff C.B. Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronicantidepressanttreatment. J. Pharmacol. Exp. Ther. 2002, 300:1085-1092.
134. Swanson C.J., Blackburn T.P., Zhang X., Zheng K., Xu Z.Q., Hökfelt T., Wolinsky T.D., Konkel M.J., Chen H., Zhong H., Walker M.W., Craig D.A., Gerald C.P., Branchek T.A. Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc. Natl. Acad. Sci. USA 2005, 102:17489-17494.
135. Tanoue A., Ito S., Honda K., Oshikawa S., Kitagawa Y., Koshimizu T.A., Mori T., Tsujimoto G. The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J. Clin. Invest. 2004, 113:302-309.
136. Tortorella C., Neri G., Nussdorfer G.G. Galaninin the regulation of the hypothalamic-pituitary-adrenal axis. Int. J. Mol. Med. 2007, 19:639-647.
137. Tschenett A., Singewald N., Carli M., Balducci C., Salchner P., Vezzani A., Herzog H., Sperk G. Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. Eur. J. Neurosci. 2003, 18:143-148.
138. Unschuld P.G., Ising M., Erhardt A., Lucae S., Kohli M., Kloiber S., Salyakina D., Thoeringer C.K., Kern N., Lieb R., Uhr M., Binder E.B., Müller-Myhsok B., Holsboer F., Keck M.E. Polymorphisms in the galanin gene are associated with symptom-severity in female patients suffering from panic disorder. J. Affect. Disord. 2008, 105:177-184.
139. van Londen L., Goekoop J.G., van Kempen G.M., Frankhuijzen-Sierevogel A.C., Wiegant V.M., van der Velde E.A., De Wied D. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 1997, 17:284-292.
140. van West D., Del-Favero J., Aulchenko Y., Oswald P., Souery D., Forsgren T., Sluijs S., Bel-Kacem S., Adolfsson R., Mendlewicz J., Van Duijn C., Deboutte D., Van Broeckhoven C., Claes S. A majorSNPhaplotype of the argininevasopressin1B receptor protects against recurrent major depression. Mol. Psychiatry 2004, 9:287-292.
141. Vitale G., Filaferro M., Ruggieri V., Pennella S., Frigeri C., Rizzi A., Guerrini R., Calò G. Anxiolytic-like effect ofneuropeptideSin the rat defensive burying. Peptides 2008, 29:2286-2289.
142. Volpi S., Rabadan-Diehl C., Aguilera G. Vasopressinergic regulation of the hypothalamic pituitary adrenal axis and stress adaptation. Stress 2004, 7:75-83.
143. Walker M.W., Wolinsky T.D., Jubian V., Chandrasena G., Zhong H., Huang X., Miller S., Hegde L.G., Marsteller D.A., Marzabadi M.R., Papp M., Overstreet D.H., Gerald C.P., Craig D.A. The novel neuropeptide Y Y5 receptor antagonist Lu AA33810 [N-[[trans-4-[(4,5-dihydro[1]benzothiepino[5,4-d]thiazol-2-yl)amino]cyclohexyl]methyl]-methanesulfonamide] exerts anxiolytic- and antidepressant-like effects in rat models of stress sensitivity. J. Pharmacol. Exp. Ther. 2009, 328:900-911.
144. Watson S., Gallagher P., Ferrier I.N., Young A.H. Post-dexamethason arginine vasopressin levels in patients with severe modd disorders. J. Psychiatr. Res. 2006, 40:353-359.
145. Weiss J.M., Boss-Williams K.A., Moore J.P., Demetrikopoulos M.K., Ritchie J.C., West C.H. Testing the hypothesis that locus coeruleus hyperactivity produces depression-related changes viagalanin. Neuropeptides 2005, 39:281.
146. Womack M.D., Barrett-Jolley R. Activation of paraventricular nucleus neurones by the dorsomedial hypothalamus via a tachykinin pathway in rats. Exp. Physiol. 2007, 92:671-676.
147. Xu Y.L., Reinscheid R.K., Huitron-Resendiz S., Clark S.D., Wang Z., Lin S.H., Brucher F.A., Zeng J., Ly N.K., Henriksen S.J., de Lecea L., Civelli O. NeuropeptideS: neuropeptidepromotingarousaland anxiolytic-like effects. Neuron 2004, 43:487-497.
148. Xu Y.L., Gall C.M., Jackson V.R., Civelli O., Reinscheid R.K. Distribution ofneuropeptideS receptor mRNA and neurochemical characteristics ofneuropeptideS-expressing neurons in the rat brain. J. Comp. Neurol. 2007, 500:84-102.
149. Yehuda R., Brand S., Yang R.K. Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping. Biol. Psychiatry 2006, 59:660-663.
150. Zhou Z., Zhu G., Hariri A.R., Enoch M.A., Scott D., Sinha R., Virkkunen M., Mash D.C., Lipsky R.H., Hu X.Z., Hodgkinson C.A., Xu K., Buzas B., Yuan Q., Shen P.H., Ferrell R.E., Manuck S.B., Brown S.M., Hauger R.L., Stohler C.S., Zubieta J.K., Goldman D. Genetic variation in humanNPYexpression affects stress response and emotion. Nature 2008, 452:997-1001.